» Articles » PMID: 25298884

Effect of Astragalus Membranaceus Extract on Diabetic Nephropathy

Overview
Specialty Endocrinology
Date 2014 Oct 10
PMID 25298884
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: Diabetic nephropathy, a microvascular complication of diabetes, is a progressive kidney disease caused by angiopathy of the capillaries in the kidney glomeruli. Herein, we report a case of a 62-year-old patient with a 30 year history of diabetes, who showed a substantial improvement in diabetic nephropathy on administration of 30 g of Astragalus membranaceus extract per day. After 1 month, estimated glomerular filtration rate increased from 47 to 72 ml/min per 1.73 m(2) and was subsequently maintained at the 1-month follow-up. Urinary protein levels also decreased following treatment. Herein, we present and discuss the evidence and mechanism of A. membranaceus on diabetic nephropathy in this patient.

Learning Points: Diabetic nephropathy is a progressive kidney disease.Angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) are currently used to prevent and delay the progression of diabetic nephropathy. However, their effects are not sufficient to prevent a decline in kidney function.Furthermore, combination therapy with an ACE inhibitor and an ARB can produce adverse effects without additional benefits.In the early phase of diabetic nephropathy, administration of Astragalus membranaceus can be a therapeutic option.

Citing Articles

Unlocking the mechanistic potential of for managing diabetic neuropathy and nephropathy.

Singh S, Singh T J Tradit Complement Med. 2025; 14(6):581-597.

PMID: 39850604 PMC: 11752125. DOI: 10.1016/j.jtcme.2024.04.009.


Therapeutic effects of Huangqi formula (Eefooton) in chronic kidney disease: clinical research and narrative literature review.

Lu K, Wu S, Lu T, Tzeng I, Kuo C, Hung Y Aging (Albany NY). 2024; 16(22):13627-13647.

PMID: 39652245 PMC: 11723655. DOI: 10.18632/aging.206170.


WTAP-mediated mA modification of TRIM22 promotes diabetic nephropathy by inducing mitochondrial dysfunction via ubiquitination of OPA1.

Zhang Z, Zhou F, Lu M, Zhang D, Zhang X, Xu S Redox Rep. 2024; 29(1):2404794.

PMID: 39314036 PMC: 11423538. DOI: 10.1080/13510002.2024.2404794.


Medicinal Herbs: Promising Immunomodulators for the Treatment of Infectious Diseases.

Alanazi H, Elasbali A, Alanazi M, El Azab E Molecules. 2023; 28(24).

PMID: 38138535 PMC: 10745476. DOI: 10.3390/molecules28248045.


Molecular Mechanistic Pathways Targeted by Natural Antioxidants in the Prevention and Treatment of Chronic Kidney Disease.

Mohany M, Ahmed M, Al-Rejaie S Antioxidants (Basel). 2022; 11(1).

PMID: 35052518 PMC: 8772744. DOI: 10.3390/antiox11010015.


References
1.
. Standards of medical care in diabetes--2013. Diabetes Care. 2012; 36 Suppl 1:S11-66. PMC: 3537269. DOI: 10.2337/dc13-S011. View

2.
Zhang J, Xie X, Li C, Fu P . Systematic review of the renal protective effect of Astragalus membranaceus (root) on diabetic nephropathy in animal models. J Ethnopharmacol. 2009; 126(2):189-96. DOI: 10.1016/j.jep.2009.08.046. View

3.
Wang S, Head J, Stevens L, Fuller J . Excess mortality and its relation to hypertension and proteinuria in diabetic patients. The world health organization multinational study of vascular disease in diabetes. Diabetes Care. 1996; 19(4):305-12. DOI: 10.2337/diacare.19.4.305. View

4.
Li M, Wang W, Xue J, Gu Y, Lin S . Meta-analysis of the clinical value of Astragalus membranaceus in diabetic nephropathy. J Ethnopharmacol. 2010; 133(2):412-9. DOI: 10.1016/j.jep.2010.10.012. View

5.
Duran-Salgado M, Rubio-Guerra A . Diabetic nephropathy and inflammation. World J Diabetes. 2014; 5(3):393-8. PMC: 4058744. DOI: 10.4239/wjd.v5.i3.393. View